Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin ... which is available in vial form or as a disposable pen.

In a joint statement, the partners set an ambitious goal: to supply affordable, high-quality insulin to over a million patients annually by 2030. For Egyptians struggling with rising healthcare costs, ...

The insulin called Afrezza is created and manufactured by MannKind Corporation, and is used to improve glycemic control in adults with diabetes mellitus.“Afrezza is a rapid-acting insulin ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

A total of 94 patients were eligible for study inclusion and randomization from July 2005 through May 2006; 45 were randomized to the vial and syringe group and 49 were randomized to the insulin ...

Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

A private pharmaceutical firm has donated five-thousand insulin vials to the Health Department for diabetic patients in Kurram. According to Secretary Health Adeel Shah, the firm handed over insulin ...

The long-acting ... its insulin active ingredient at a reduced price and provides pro bono technology transfer. This will enable Eva Pharma to locally formulate and package insulin vials and ...

The picture shows an ampule of quick-acting ... Insulin, discovered over a century ago, was originally intended to be affordable. However, today's prices, which can reach up to $700 per vial ...

The INHALE-1 study is a 26-week, open-label clinical trial that randomized 230 subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA ...